Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. aTyr Pharma's Total Liabilities for the quarter that ended in Dec. 2023 was $30.18 Mil. aTyr Pharma's Total Assets for the quarter that ended in Dec. 2023 was $120.65 Mil.
Therefore, aTyr Pharma's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 was 0.25.
aTyr Pharma Liabilities-to-Assets Historical Data
The historical data trend for aTyr Pharma's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of aTyr Pharma's Liabilities-to-Assets
For the Biotechnology subindustry, aTyr Pharma's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
aTyr Pharma's Liabilities-to-Assets Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, aTyr Pharma's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where aTyr Pharma's Liabilities-to-Assets falls into.
aTyr Pharma Liabilities-to-Assets Calculation
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
aTyr Pharma's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
aTyr Pharma Liabilities-to-Assets Related Terms
Thank you for viewing the detailed overview of aTyr Pharma's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LIFE has been successfully added to your 